KevinBruceSandersMD(He/Him)

Psychiatry • White House, TN

Child & Adolescent Psychiatry, Neuropsychiatry, Psychopharmacology

Physician

Join to view full profile

Dr. Sanders is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sanders' full profile

Already have an account?

Office
3023 US-31W
White House, TN 37188
Phone+1 615-708-6368

Summary

I am a general and child psychiatrist working to develop safe, effective and much needed treatments for patients with psychiatric and neurological disorders.

Clinical Expertise

Learning disorders, Angelman syndrome, Neurodevelopmental abnormalities, Neurodevelopmental disabilities, Autism spectrum disorders, Schizophrenia, Behavior therapy, Attention-deficit/hyperactivity disorder, Clinical research, Mood disorders, Anxiety disorders, Psychiatry, Pervasive developmental disorders, Clincial trials, Precision Psychiatry, Apathy, Neuroplastogens, Digital Theraputics, Digital Biomarkers, Stratification Psychiatry

Education & Training

Duke University HospitalFellowship, Child and Adolescent Psychiatry, 2000 - 2002
University of North Carolina HospitalsResidency, Psychiatry, 1997 - 2000
University of Tennessee Health Science Center College of MedicineClass of 1997
University of Tennessee SystemB.S., Biology, 1990 - 1993
Lipscomb UniversityNo degree, 1989 - 1990

Certifications & Licensure

TN State Medical License 2009 - 2024
AL State Medical License 2008 - 2012
FL State Medical License 2002 - 2012
NC State Medical License 1999 - 2003
AOA Board of Neurology and Psychiatry Psychiatry

Awards, Honors, & Recognition

Dozier Award for Excellence in Teaching in Child & Adolescent Psychiatry Vanderbilt Child Psychiatry Fellowship Program, 2010, 2016
Master Clinical Teacher Vanderbilt University Medical School, 2012-2014
Chief Chid and Adolescent Psychiatry Fellow Duke University, 2001-2002
Outstanding Mental Health Professional of the Year Mental Health America of Middle Tennessee, 2016
Join now to see all

Clinical Trials

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Start of enrollment: 2008 Mar 01
Completed
Phase 4
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome Start of enrollment: 2008 Nov 01
Completed
Phase 2
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders Start of enrollment: 2009 Feb 01
Completed
Phase 2
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome Start of enrollment: 2009 Nov 01
Terminated
Phase 2
A Study With RO4917523 in Patients With Fragile X Syndrome Start of enrollment: 2009 Nov 01
Completed
Phase 2
An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders Start of enrollment: 2010 Feb 01
Terminated
Phase 2
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome Start of enrollment: 2011 May 01
Completed
Phase 3
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome Start of enrollment: 2011 Jun 01
Completed
Phase 3
A Study of RO4917523 in Patients With Fragile X Syndrome Start of enrollment: 2012 May 01
Completed
Phase 2
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Start of enrollment: 2012 Sep 01
Completed
Phase 2
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Start of enrollment: 2012 Oct 01
Terminated
Phase 2
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders Start of enrollment: 2011 Nov 01
Terminated
Phase 3
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome Start of enrollment: 2013 Feb 01
Completed
Phase 2
A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD) Start of enrollment: 2013 Sep 01
Completed
Phase 2
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Start of enrollment: 2013 Apr 01
Completed
Phase 3
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome Start of enrollment: 2014 Jan 01
Completed
Phase 2
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors Start of enrollment: 2014 Aug 01
Completed
Phase 2
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Start of enrollment: 2014 Mar 02
Completed
Improving Hospitalizations for Children With ASD Start of enrollment: 2015 Jan 01
Completed
Not Applicable
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study) Start of enrollment: 2015 May 13
Completed
Phase 3
A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age Start of enrollment: 2015 Oct 28
Terminated
Phase 2
Children's Autism Metabolome Project Start of enrollment: 2015 Aug 01
Active, not recruiting
An Open Label Study of CM-AT for the Treatment of Children With Autism Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD) Start of enrollment: 2016 Nov 21
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder.
Stephen K Siecinski, Stephanie N Giamberardino, Marina Spanos, Annalise C Hauser, Jason R Gibson
Autism Research. 2023-03-01
22 citations
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
Eric Hollander, Suma Jacob, Roger Jou, Nora McNamara, Linmarie Sikich
JAMA Psychiatry. 2022-08-01
14 citations
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-contr...
Suma Jacob, Jeremy Veenstra-VanderWeele, Declan Murphy, James McCracken, Janice Smith
The Lancet. Psychiatry. 2022-03-01

Journal Articles

Comparing oxytocin and cortisol regulation in a double-blind, placebo-controlled, hydrocortisone challenge pilot study in children with autism and typical development
Corbett BA, Bales KL, Swain D, Sanders K, Weinstein TA, Muglia LJ, J Neurodev Disord, 1/18/2016
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder : A Randomized Clinical Trial
Anagnostou E, Aman MG, Handen BL, Sanders KB, Shui A, Hollway JA, Brian J, Arnold LE, Capano L, Hellings JA, Butter E, Mankad D, Tumuluru R, Kettel J, Newsom CR, Hadji..., JAMA Psychiatry, 1/1/2016
N-Acetylcysteine as Treatment for Self-Injurious Behaviors in a Child with Autism
Marler SE, Sanders KB, Veenstra-VanderWeele J, Journal of Child and Adolescent Psychopharmacology, 5/2014
Retrospective case series of oxcarbazepine for irritability or problem behavior symptoms in autism spectrum disorder
Douglas JF, Sanders KB, Benneyworth MH, Smith JL, DeJean VM, McGrew SG, Veenstra-VanderWeele J (, Journal of Autism and Developmental Disorders, 1/1/2013
‘Identity crisis’ in a young man with autism
Warren ZE, Sanders KB, Veenstra-VanderWeele J, American Journal of Psychiatry, 1/1/2010
Join now to see all

Lectures

Psychopharm options in the ASD population
Society for Developmental and Behavioral Pediatrics Annual Meeting
Improving Hospitalizations for Children with ASD - implementation of ABA to decrease cost and length of stay in VCH and VPH
Vanderbilt Psychiatry Grand Rounds - 10/23/2015
Improving Hospitalizations for Children with ASD and Effects of Medication on Behavioral Therapies
Tennessee Annual ABA State Conference - 9/2015
Cultural Competency and Communication Skills in Interdisciplinary Management of a Complex Child
Vanderbilt Psychiatry Grand Rounds - 3/2010
Inpatient Discharge Planning and Risk of Suicide
Vanderbilt Psychiatry M&M Conference - 3/2009
Join now to see all

Press Mentions

Autism: In Search of New Drug TargetsApril 21st, 2016

Professional Memberships

Industry Relationships

Global Head of Neurodevelopment- Product Development, Roche/GenentechWorking to develop safe and effective medication options for individuals with developmental disorders.Disclosure: Roche/Genentech2017 - 2020

External Links

MEND Clinic at VUMChttps://medschool.vanderbilt.edu/mend/
TRIAD at VKChttp://vkc.mc.vanderbilt.edu/VKC/triad/